NO20004781L - Svekkede bakterier anvendelige i vaksiner - Google Patents

Svekkede bakterier anvendelige i vaksiner

Info

Publication number
NO20004781L
NO20004781L NO20004781A NO20004781A NO20004781L NO 20004781 L NO20004781 L NO 20004781L NO 20004781 A NO20004781 A NO 20004781A NO 20004781 A NO20004781 A NO 20004781A NO 20004781 L NO20004781 L NO 20004781L
Authority
NO
Norway
Prior art keywords
vaccines
attenuated bacteria
useful
bacteria useful
gene
Prior art date
Application number
NO20004781A
Other languages
English (en)
Other versions
NO327609B1 (no
NO20004781D0 (no
Inventor
Steven Neville Chatfield
Original Assignee
Peptide Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptide Therapeutics Ltd filed Critical Peptide Therapeutics Ltd
Publication of NO20004781D0 publication Critical patent/NO20004781D0/no
Publication of NO20004781L publication Critical patent/NO20004781L/no
Publication of NO327609B1 publication Critical patent/NO327609B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • C12N15/03—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

Bakterie som er blitt svekket ved en ikke-reverserende mutasjon i aroC-genet, ompF-genet og ompC-genet. Bakterien er nyttig som vaksine. Bakterien kan f.eks. være en svekket stamme av E. coli som er nyttig ved vaksinasjon mot diaré.
NO20004781A 1998-03-25 2000-09-25 Svekkede muterte bakterier anvendelige i vaksiner. NO327609B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9806449.6A GB9806449D0 (en) 1998-03-25 1998-03-25 Attenuated bacteria useful in vaccines
PCT/GB1999/000935 WO1999049026A1 (en) 1998-03-25 1999-03-25 Bacteria attenuated by a non-reverting mutation in each of the aroc, ompf and ompc genes, useful as vaccines

Publications (3)

Publication Number Publication Date
NO20004781D0 NO20004781D0 (no) 2000-09-25
NO20004781L true NO20004781L (no) 2000-11-08
NO327609B1 NO327609B1 (no) 2009-08-31

Family

ID=10829280

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004781A NO327609B1 (no) 1998-03-25 2000-09-25 Svekkede muterte bakterier anvendelige i vaksiner.

Country Status (19)

Country Link
US (1) US6902906B1 (no)
EP (1) EP1066376B1 (no)
JP (1) JP4516210B2 (no)
KR (1) KR100628657B1 (no)
AT (1) ATE296881T1 (no)
AU (1) AU763683B2 (no)
CA (1) CA2323576C (no)
CZ (1) CZ301520B6 (no)
DE (1) DE69925585T2 (no)
DK (1) DK1066376T3 (no)
ES (1) ES2244182T3 (no)
GB (1) GB9806449D0 (no)
HU (1) HU225644B1 (no)
NO (1) NO327609B1 (no)
NZ (1) NZ507077A (no)
PL (1) PL196076B1 (no)
PT (1) PT1066376E (no)
WO (1) WO1999049026A1 (no)
ZA (1) ZA200004987B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138237B1 (en) 2000-05-19 2006-11-21 Cedars-Sinai Medical Center Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen
WO2002057780A1 (en) * 2001-01-18 2002-07-25 Newcastle University Ventures Ltd. Biosensor with covalently attached membrane-spanning proteins
GB0121998D0 (en) 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
US7297338B2 (en) * 2003-05-14 2007-11-20 Wyeth Avian vaccine composition for the protection of poultry against disease and infection caused by E. coli and Salmonella
US7357935B2 (en) * 2003-05-14 2008-04-15 Wyeth Avian E. coli vaccine for protection against colibacillosis
CN101378780A (zh) * 2006-02-01 2009-03-04 Sbl疫苗公司 重组细菌中的肠产毒性大肠杆菌定居因子(cf)抗原
JP2008054614A (ja) * 2006-09-01 2008-03-13 Nippon Inst For Biological Science 鶏大腸菌由来弱毒変異株、鶏大腸菌対策用ワクチン、免疫方法及び鶏用ワクチンベクター
EP2857038B1 (en) 2006-09-18 2019-04-10 The Board of Trustees of the University of Arkansas Compositions and methods of enhancing immune responses
US9125854B2 (en) * 2007-10-30 2015-09-08 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
PT2214701T (pt) 2007-11-01 2016-11-02 Univ Guelph Composições e métodos de potenciar respostas imunes a eimeria
NO2525817T3 (no) 2010-01-21 2018-01-06
BR112012031211A2 (pt) 2010-06-09 2018-01-30 Univ Arkansas métodos e vacina para reduzir a infecção causada pelo campylobacter
WO2014037445A1 (en) * 2012-09-05 2014-03-13 Lohmann Animal Health Gmbh Preparation of live vaccines
CN104995292A (zh) 2012-12-07 2015-10-21 洛曼动物健康有限责任公司 活疫苗制备
EP2956165B1 (en) 2013-02-14 2019-09-11 The Board of Trustees of the University of Arkansas Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
CN105142653B (zh) 2013-03-15 2019-11-15 阿肯色大学评议会 增强对肠病原体免疫应答的组合物和方法
AR108688A1 (es) 2016-05-03 2018-09-19 Univ Arkansas Vector de vacuna de levadura que incluye polipéptidos inmunoestimuladores y antigénicos, métodos para su uso

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8730037D0 (en) 1987-12-23 1988-02-03 Wellcome Found Vaccines
GB8912330D0 (en) 1989-05-30 1989-07-12 Wellcome Found Live vaccines
ATE111957T1 (de) * 1990-02-06 1994-10-15 Pasteur Institut Transformiertes shigella.
GB9007194D0 (en) * 1990-03-30 1990-05-30 Wellcome Found Live vaccines
ATE180280T1 (de) * 1991-03-05 1999-06-15 Wellcome Found Expression rekombinanter proteine in attenuierten bakterien

Also Published As

Publication number Publication date
AU763683B2 (en) 2003-07-31
EP1066376A1 (en) 2001-01-10
DK1066376T3 (da) 2005-10-03
JP4516210B2 (ja) 2010-08-04
PT1066376E (pt) 2005-10-31
HUP0105430A2 (hu) 2002-04-29
NZ507077A (en) 2002-10-25
CA2323576A1 (en) 1999-09-30
JP2002507414A (ja) 2002-03-12
HU225644B1 (en) 2007-05-02
DE69925585D1 (de) 2005-07-07
PL343246A1 (en) 2001-07-30
CA2323576C (en) 2010-12-07
PL196076B1 (pl) 2007-12-31
ATE296881T1 (de) 2005-06-15
KR100628657B1 (ko) 2006-09-26
KR20010042175A (ko) 2001-05-25
ZA200004987B (en) 2001-10-31
CZ20003470A3 (cs) 2001-07-11
DE69925585T2 (de) 2006-07-13
WO1999049026A1 (en) 1999-09-30
ES2244182T3 (es) 2005-12-01
HUP0105430A3 (en) 2004-10-28
US6902906B1 (en) 2005-06-07
NO327609B1 (no) 2009-08-31
GB9806449D0 (en) 1998-05-27
EP1066376B1 (en) 2005-06-01
AU3045899A (en) 1999-10-18
NO20004781D0 (no) 2000-09-25
CZ301520B6 (cs) 2010-03-31

Similar Documents

Publication Publication Date Title
DK1066376T3 (da) Svækkede bakterier ved hjælp af en ikke-reverterende mutation i hver af AROC-, OMPF- og OMPC-generne, der er anvendelige i vacciner
KR937000640A (ko) 생 백신
ATE219948T1 (de) Rekombinante impfstoffe die immunogene attenuierte rpos-positiv phentotyp bakterien enthalten
WO2001070247A3 (en) Salmonella vaccine materials and methods
ATE187078T1 (de) Nichttoxisches schleimhautadjuvans
BRPI9700768B8 (pt) vacina viva para combater infecção por streptococcus em cavalos.
NO921729D0 (no) Stabile pura-vektorer og anvendelser derav
DK1425037T3 (da) Bakteriel vaccine
HUP0302612A2 (hu) Salmonella vakcina
ATE103331T1 (de) Vakzine.
WO2007112518A8 (en) Live attenuated salmonella vaccine
Andoh et al. Comparative virulence of phase I and II Coxiella burnetii in immunodeficient mice
AU6992200A (en) Vaccines
Schwenteit et al. Construction of Aeromonas salmonicida subsp. achromogenes AsaP1‐toxoid strains and study of their ability to induce immunity in Arctic char, Salvelinus alpinus L.
BG104759A (en) Streptomyces avermitilis gene directing the ratio of b2:b1 avermectins
AU2001258579A1 (en) Virulence genes, proteins, and their use
HK1030016A (en) Bacteria attenuated by a non-reverting mutation in each of the aroc, ompf and ompc genes, useful as vaccines
BR9809974A (pt) Vacinas vivas atenuadas
AU1853995A (en) Vaccine compositions
ATE277632T1 (de) Impfstoffe die abgeschwächte bakterien enthalten
UA29201A (uk) Вакцинний штам бактерій bacillus anthracis сб-072 проти сибірки тварин
Stackebrandt et al. Myceligenerans
UA33502A (uk) Спосіб виготовлення інактивованої вакцини проти сальмонельозів тварин

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees